177 related articles for article (PubMed ID: 7874340)
1. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
Sataloff DM; Mason BA; Prestipino AJ; Seinige UL; Lieber CP; Baloch Z
J Am Coll Surg; 1995 Mar; 180(3):297-306. PubMed ID: 7874340
[TBL] [Abstract][Full Text] [Related]
2. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide combined with neoadjuvant chemotherapy in angiosarcoma of the breast with complete pathologic response: case report and review of literature.
Alvarado-Miranda A; Bacon-Fonseca L; Ulises Lara-Medina F; Maldonado-Martínez H; Arce-Salinas C
Breast Care (Basel); 2013 Mar; 8(1):74-6. PubMed ID: 24715848
[TBL] [Abstract][Full Text] [Related]
4. Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer.
Ashford R; Priestman T; Mott T; Bottomley JM
Cancer Immunol Immunother; 1986; 23(3):217-9. PubMed ID: 3791306
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Chevallier B; Roche H; Olivier JP; Chollet P; Hurteloup P
Am J Clin Oncol; 1993 Jun; 16(3):223-8. PubMed ID: 8338056
[TBL] [Abstract][Full Text] [Related]
6. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher B; Bryant J; Wolmark N; Mamounas E; Brown A; Fisher ER; Wickerham DL; Begovic M; DeCillis A; Robidoux A; Margolese RG; Cruz AB; Hoehn JL; Lees AW; Dimitrov NV; Bear HD
J Clin Oncol; 1998 Aug; 16(8):2672-85. PubMed ID: 9704717
[TBL] [Abstract][Full Text] [Related]
7. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Sinn HP; Schmid H; Junkermann H; Huober J; Leppien G; Kaufmann M; Bastert G; Otto HF
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):552-8. PubMed ID: 8001751
[TBL] [Abstract][Full Text] [Related]
8. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
Fisher B; Brown A; Mamounas E; Wieand S; Robidoux A; Margolese RG; Cruz AB; Fisher ER; Wickerham DL; Wolmark N; DeCillis A; Hoehn JL; Lees AW; Dimitrov NV
J Clin Oncol; 1997 Jul; 15(7):2483-93. PubMed ID: 9215816
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cleaved caspase-3 and Ki-67 index on diagnostic biopsy in response to neoadjuvant chemotherapy in the context of post-treatment tumour ypT stage, ypN stage, grade, and molecular subtype.
Nanev V; Milev H; Dimitrova D; Naneva S; Strashilov SA; Yordanov A; Mihailova M; Ivanova S; Karcheva M; Ivanov I
Prz Menopauzalny; 2024 Mar; 23(1):31-40. PubMed ID: 38690065
[TBL] [Abstract][Full Text] [Related]
10. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.
Arqueros C; Gallardo A; Vidal S; Osuna-Gómez R; Tibau A; Lidia Bell O; Ramón Y Cajal T; Lerma E; Lobato-Delgado B; Salazar J; Barnadas A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473874
[TBL] [Abstract][Full Text] [Related]
11. Localised breast cancer: neoadjuvant chemotherapy impact evaluation on the pathological complete response (PCR) in a lower middle-income country.
Adjadé G; Tafenzi HA; Jouihri H; Tamimi NSA; Bennouna Y; Négamiyimana G; Cisse K; Essadi I; Fadli ME; Belbaraka R
Ecancermedicalscience; 2023; 17():1648. PubMed ID: 38414939
[TBL] [Abstract][Full Text] [Related]
12. [Adequacy of histopathology request forms and pathological reports of breast cancer surgical specimens in Benin].
Gnangnon FHR; Seidou F; Laleye CM; Odidi FP; Flenon Nakou A; Tonato Bagnan JA; Denakpo JL; Houinato DS; Gbessi DG
Med Trop Sante Int; 2023 Dec; 3(4):. PubMed ID: 38390014
[TBL] [Abstract][Full Text] [Related]
13. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
López-Velazco JI; Manzano S; Otaño M; Elorriaga K; Bultó N; Herrero J; Lahuerta A; Segur V; Álvarez-López I; Caffarel MM; Urruticoechea A
Breast Cancer Res; 2024 Jan; 26(1):3. PubMed ID: 38173005
[TBL] [Abstract][Full Text] [Related]
14. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
Litton JK; Regan MM; Pusztai L; Rugo HS; Tolaney SM; Garrett-Mayer E; Amiri-Kordestani L; Basho RK; Best AF; Boileau JF; Denkert C; Foster JC; Harbeck N; Jacene HA; King TA; Mason G; O'Sullivan CC; Prowell TM; Richardson AL; Sepulveda KA; Smith ML; Tjoe JA; Turashvili G; Woodward WA; Butler LP; Schwartz EI; Korde LA
J Clin Oncol; 2023 Sep; 41(27):4433-4442. PubMed ID: 37433103
[TBL] [Abstract][Full Text] [Related]
15. Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers.
Sánchez-Méndez JI; Horstmann M; Méndez N; Frías L; Moreno E; Yébenes L; Roca MJ; Hernández A; Martí C
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345094
[TBL] [Abstract][Full Text] [Related]
16.
Quartuccio N; Alongi P; Urso L; Ortolan N; Borgia F; Bartolomei M; Arnone G; Evangelista L
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345052
[TBL] [Abstract][Full Text] [Related]
17. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer.
Qian XL; Xia XQ; Li YQ; Jia YM; Sun YY; Song YM; Xue HQ; Hao YF; Wang J; Wang XZ; Liu CY; Zhang XM; Zhang LN; Guo XJ
Sci Rep; 2023 Jun; 13(1):9256. PubMed ID: 37286786
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer.
Oliveira C; Oliveira F; Vaz SC; Marques HP; Cardoso F
Br J Radiol; 2023 Jun; 96(1146):20220655. PubMed ID: 36867773
[TBL] [Abstract][Full Text] [Related]
19. The Value of Semiquantitative Parameters Derived from
Urso L; Evangelista L; Alongi P; Quartuccio N; Cittanti C; Rambaldi I; Ortolan N; Borgia F; Nieri A; Uccelli L; Schirone A; Panareo S; Arnone G; Bartolomei M
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497351
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a personalized nomogram of ultrasound for pretreatment prediction of breast cancer patients sensitive to neoadjuvant chemotherapy.
Zhang MQ; Du Y; Zha HL; Liu XP; Cai MJ; Chen ZH; Chen R; Wang J; Wang SJ; Zhang JL; Li CY
Br J Radiol; 2022 Dec; 95(1140):20220626. PubMed ID: 36378247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
